ClinicalTrials.gg
TerminatedNCT02557516Updated Dec 17, 2019Results posted

Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL

A Phase 1/2 interventional study of monalizumab in Chronic Lymphocytic Leukemia, sponsored by Innate Pharma. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-17.

Sponsored by Innate Pharma · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States — 138 open to participants now, 252 under way, 34 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United States.

Enrollment
876th of 1,298
22 · median 36
Started
2015
with 49 others
Phase 1/2
172 of 1,501
15 open now
Registered
1,093rd of 1,501
by date

Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, this one is the 876th largest by enrollment of the 1,298 interventional ones that give a count, is one of 50 that started in 2015, is one of 172 in phase 1/2, and was the 1,093rd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

138 of the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States are open now. Recruiting first, the newest first:

133 more — sign in →

All 138 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, or all of them as a file.
02

Study summary

Combination study of monalizumab (IPH2201) with Ibrutinib in relapsed, refractory or previously untreated Chronic Lymphocytic Leukemia (CLL) patients in 2 parts :

  • phase 1 : a 3+3 design to assess the Maximum Tolerated Dose (MTD)
  • phase 2: to evaluate the anti-leukemic activity of the combination
Read the detailed description

This trial was designated to test the hypothesis that the combination of ibrutinib and IPH2201 will result in a substantial complete response (CR) rate, especially CR without minimal residual disease (MRD), as this has been shown to be associated with long-term clinical benefit.

Up to 45 patients were planned to be enrolled. During the phase 1 part a 3+3 dose escalation design was employed. Four doses were planned to be assessed if the Maximum Tolerated Dose (MTD) was not previously reached: 1, 2, 4 and 10 mg/kg.

During phase 2 part, patients received monalizumab in combination with ibrutinib; monalizumab was given at the dose recommended upon completion of the phase I portion.

The primary objective of the phase 1 was to assess the safety of monalizumab given intravenously as a single agent and in combination with ibrutinib in patients with relapsed, refractory or previously untreated Chronic Lymphocytic Leukemia.

The primary objective of the phase 2 was to evaluate the anti-leukemic activity of the combination of monalizumab and ibrutinib in patients with relapsed, refractory or previously untreated Chronic Lymphocytic Leukemia.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL)
  • , refractory or previously untreated CLL
  • CLL requiring treatment; patients must be eligible for ibrutinib therapy
  • Age > = 18 years
  • performance status of 0-2
  • > = 3 months
  • Adequate liver and renal function
  • Negative serum pregnancy test within 72 hours before starting study treatment in women with . Women of child-bearing potential and men must agree to use adequate prior to study entry and for the duration of the study participation
  • Ability to understand a written informed and consent document
  • Signed prior to any protocol-specific procedures

Exclusion criteria

Exclusion Criteria:

  • Patients who have previously received ibrutinib or another inhibitor of Bruton's tyrosine kinase (BTK)
  • History of allergic reactions attributed to compounds or similar chemical or biological composition to ibrutinib
  • Central nervous system involvement of the CLL
  • Abnormal hematological function which is not due to bone marrow failure related to the CLL
  • Patients requiring a treatment by oral vitamin K antagonists
  • Serious uncontrolled medical disorder
  • Medical condition or organ system dysfunction which, in the investigator opinion, could interfere with absorption or metabolism of ibrutinib
  • Moderate or severe hepatic impairment
  • Active auto-immune disease
  • Abnormal cardiac status
  • Pregnant women are excluded from study
  • Current active infectious disease
  • History of another within 3 years
  • History of allogeneic stem cell or solid organ transplantation
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Phase 1 Level 1 - 1 mg/kg

    In phase 1, Monalizumab given at the first dose level of 1 mg/kg.

    Drug: monalizumab

  • Experimental
    Phase 1 Level 2 - 2 mg/kg

    In phase 1, Monalizumab given at the second dose level of 2 mg/kg.

    Drug: monalizumab

  • Experimental
    Phase 1 Level 3 - 4 mg/kg

    In phase 1, Monalizumab given at the third dose level of 4 mg/kg.

    Drug: monalizumab

  • Experimental
    Phase 2 RP2D - 2 mg/kg

    In phase 2, Monalizumab given at the Recommended Phase 2 Dose (RP2D) of 2 mg/kg, selected by a safety committee.

    Drug: monalizumab

Interventions

  • During phase 1, patients received monalizumab, IV, at the dose of 1, 2 or 4mg/kg, as a single agent during 4 weeks and thereafter combined with ibrutinib 420 mg, orally, once daily, during 52 weeks. During phase 2, patients received monalizumab, IV, at the dose recommended upon completion of phase 1, combined with ibrutinib 420 mg orally, once daily, from the first cycle, during 52 weeks. In both parts of the trial, the first 4 administrations of monalizumab (from week 0 to week 6) occured every 2 weeks. From the 5th administration monalizumab was administered every 4 weeks.

    Also known as: Anti-NKG2A, IPH2201

06

What researchers measure

Primary outcomes

  1. Number of Dose Limiting Toxicities

    Number of dose-limiting toxicities, measured during the phase 1, dose escalation, part of the study.

    Time frame: 8 weeks

  2. Rate of Complete Response (CR)

    The rate of complete response (CR) was evaluated using the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) grading scale and confirmed by a bone marrow biopsy. Per International Workshop on Chronic Lymphocytic Leukemia (IWCLL), Complete Response (CR) is defined as lymphocytes \<4x109/l, absence of lymphadenopathy, hepatomegaly and splenomegaly at CT scan, no constitutional symptoms, no cytopenia, normocellular bone marrow. Partial Response (PR) is a reduction \> 50% in lymphocytes, lymphadenopathy, spleen or liver, no cytopenia. PD if appearance of any new lesion, or increase in lymphocytes \> 50%, or occurrence of cytopenia attributable to CLL.

    Time frame: CR assessed 52 weeks after the beginning of combination treatment

Secondary outcomes

  1. Best Overall Response / Remission Rates

    Measure of best overall response at any time during the study. cCR: confirmed complete response/remission; uCR: unconfirmed complete response / remission; PR: partial response/remission; SD: stable disease; PD: progressive disease. Per International Workshop on Chronic Lymphocytic Leukemia (IWCLL), Complete Response (CR) is defined as lymphocytes \<4x109/l, absence of lymphadenopathy, hepatomegaly and splenomegaly at CT scan, no constitutional symptoms, no cytopenia, normocellular bone marrow. Partial Response (PR) is a reduction \> 50% in lymphocytes, lymphadenopathy, spleen or liver, no cytopenia. PD if appearance of any new lesion, or increase in lymphocytes \> 50%, or occurrence of cytopenia attributable to CLL. In order to have a confirmed CR (cCR), the CR must be confirmed by a scan and a bone marrow assessment assessed at least 2 months after the first occurrence of CR. Otherwise it would be an unconfirmed CR (uCR).

    Time frame: From beginning of study drug treatment to the end of study (up to 24 months)

  2. Duration of Remission

    The duration of remission (DOR) is defined as the time from the date of first evaluation of the remission (cCR, uCR or PR) to the first documentation of progressive disease, relapsed disease or death. In case an assessment of progressive / relapsed disease or death does not exist, the DOR was censored at the time of the last disease assessment date. The DOR was calculated only for the patients with a remission that was assessed at 52 weeks.

    Time frame: Up to 24 months

  3. Progression Free Survival

    The Progression Free Survival (PFS) is defined as the time from first dose administration until the occurrence of progressive disease, relapsed disease or death from any cause. Patients without an event at the time of the analyse were censored at his or her last disease assessment date. Patients with no post-Baseline assessment were censored at the day of the first dose administration.

    Time frame: Up to 24 months

  4. Overall Survival

    The overall survival (OS) is defined as the time from first dose administration until death from any cause. Alive patients were censored at the most recent date they were known to be alive. Subjects with no assessment post-Baseline were censored at the day of the first dose administration.

    Time frame: Up to 24 months.

07

Results

Posted Dec 17, 2019
Limitations and caveats
Due to early termination some of the secondary endpoints could not be evaluated.

Participant flow

It was anticipated that up to 24 patients (3 to 6 patients; 4 dose levels) would be enrolled in Phase 1 part of the study and up to 24 patients in the Phase 2 part with a total of up to 45 patients in the trial. A total of 22 patients were actually enrolled in the study: 13 patients in the Phase 1 part and 9 patients in the Phase 2 part.

Participant flow — Overall Study
MilestonePhase 1 Level 1 - 1 mg/kgPhase 1 Level 2 - 2 mg/kgPhase 1 Level 3 - 4 mg/kgPhase 2 RP2D - 2 mg/kg
Started3649
Completed2100
Not completed1549
Withdrew: Adverse event1021
Withdrew: Disease progression0200
Withdrew: Physician decision0200
Withdrew: Sponsor decision0128

Outcome measures

PrimaryNumber of Dose Limiting Toxicities

Number of dose-limiting toxicities, measured during the phase 1, dose escalation, part of the study.

Time frame:
8 weeks
Reported as:
Number · Dose Limiting Toxicy
Number of Dose Limiting Toxicities
Dose Limiting ToxicyPhase 1 Level 1 - 1 mg/kgPhase 1 Level 2 - 2 mg/kgPhase 1 Level 3 - 4 mg/kg
Number of Dose Limiting Toxicities012
PrimaryRate of Complete Response (CR)

The rate of complete response (CR) was evaluated using the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) grading scale and confirmed by a bone marrow biopsy. Per International Workshop on Chronic Lymphocytic Leukemia (IWCLL), Complete Response (CR) is defined as lymphocytes \<4x109/l, absence of lymphadenopathy, hepatomegaly and splenomegaly at CT scan, no constitutional symptoms, no cytopenia, normocellular bone marrow. Partial Response (PR) is a reduction \> 50% in lymphocytes, lymphadenopathy, spleen or liver, no cytopenia. PD if appearance of any new lesion, or increase in lymphocytes \> 50%, or occurrence of cytopenia attributable to CLL.

Time frame:
CR assessed 52 weeks after the beginning of combination treatment
Reported as:
Count of participants · Participants
Rate of Complete Response (CR)
ParticipantsPhase 1 Level 1 - 1 mg/kgPhase 1 Level 2 - 2 mg/kgPhase 1 Level 3 - 4 mg/kgPhase 2 RP2D - 2 mg/kg
Rate of Complete Response (CR)1100
SecondaryBest Overall Response / Remission Rates

Measure of best overall response at any time during the study. cCR: confirmed complete response/remission; uCR: unconfirmed complete response / remission; PR: partial response/remission; SD: stable disease; PD: progressive disease. Per International Workshop on Chronic Lymphocytic Leukemia (IWCLL), Complete Response (CR) is defined as lymphocytes \<4x109/l, absence of lymphadenopathy, hepatomegaly and splenomegaly at CT scan, no constitutional symptoms, no cytopenia, normocellular bone marrow. Partial Response (PR) is a reduction \> 50% in lymphocytes, lymphadenopathy, spleen or liver, no cytopenia. PD if appearance of any new lesion, or increase in lymphocytes \> 50%, or occurrence of cytopenia attributable to CLL. In order to have a confirmed CR (cCR), the CR must be confirmed by a scan and a bone marrow assessment assessed at least 2 months after the first occurrence of CR. Otherwise it would be an unconfirmed CR (uCR).

Time frame:
From beginning of study drug treatment to the end of study (up to 24 months)
Reported as:
Count of participants · Participants
Best Overall Response / Remission Rates
ParticipantsPhase 1 Level 1 - 1 mg/kgPhase 1 Level 2 - 2 mg/kgPhase 1 Level 3 - 4 mg/kgPhase 2 RP2D - 2 mg/kg
cCR1100
uCR0100
PR2326
SD0113
PD0000
SecondaryDuration of Remission

The duration of remission (DOR) is defined as the time from the date of first evaluation of the remission (cCR, uCR or PR) to the first documentation of progressive disease, relapsed disease or death. In case an assessment of progressive / relapsed disease or death does not exist, the DOR was censored at the time of the last disease assessment date. The DOR was calculated only for the patients with a remission that was assessed at 52 weeks.

Time frame:
Up to 24 months
Reported as:
Median · Month
Duration of Remission
MonthEfficacy Population
Duration of RemissionNA (NA to NA)
SecondaryProgression Free Survival

The Progression Free Survival (PFS) is defined as the time from first dose administration until the occurrence of progressive disease, relapsed disease or death from any cause. Patients without an event at the time of the analyse were censored at his or her last disease assessment date. Patients with no post-Baseline assessment were censored at the day of the first dose administration.

Time frame:
Up to 24 months
Reported as:
Median · Month
Progression Free Survival
MonthITT / Safety Population
Progression Free SurvivalNA (NA to NA)
SecondaryOverall Survival

The overall survival (OS) is defined as the time from first dose administration until death from any cause. Alive patients were censored at the most recent date they were known to be alive. Subjects with no assessment post-Baseline were censored at the day of the first dose administration.

Time frame:
Up to 24 months.
Reported as:
Median · Month
Overall Survival
MonthAll ITT / Safety Population
Overall SurvivalNA (NA to NA)

Adverse events

Collected over The occurrences of Adverse Events were recorded from the time of signed informed consent until the end of the patient's participation to the trial (up to 24 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1 mg/kg0/3 (0%)2/3 (66.7%)3/3 (100%)
2 mg/kg0/15 (0%)5/15 (33.3%)15/15 (100%)
4 mg/kg0/4 (0%)3/4 (75%)4/4 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
Event1 mg/kg2 mg/kg4 mg/kg
Supraventricular tachycardiaCardiac disorders1/30/150/4
UrosepsisInfections and infestations1/30/150/4
Myelodysplastic syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30/150/4
Large intestinal haemorrhageGastrointestinal disorders0/30/151/4
PyrexiaGeneral disorders0/30/151/4
Amylase increasedInvestigations0/30/151/4
EpistaxisRespiratory, thoracic and mediastinal disorders0/30/151/4
HypoxiaRespiratory, thoracic and mediastinal disorders0/30/151/4
Lower gastrointestinal haemorrhageGastrointestinal disorders0/31/150/4
SinusitisInfections and infestations0/31/150/4
Most frequent other events
Showing 10 of 159
Most frequent other events
Event1 mg/kg2 mg/kg4 mg/kg
DiarrhoeaGastrointestinal disorders2/39/154/4
ContusionInjury, poisoning and procedural complications3/38/150/4
Decreased appetiteMetabolism and nutrition disorders2/35/150/4
Back painMusculoskeletal and connective tissue disorders2/31/150/4
MyalgiaMusculoskeletal and connective tissue disorders2/37/151/4
EpistaxisRespiratory, thoracic and mediastinal disorders2/35/150/4
Nasal congestionRespiratory, thoracic and mediastinal disorders2/32/152/4
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/34/150/4
ArthralgiaMusculoskeletal and connective tissue disorders1/38/152/4
CoughRespiratory, thoracic and mediastinal disorders1/38/152/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase 1 Level 1 - 1 mg/kgPhase 1 Level 2 - 2 mg/kgPhase 1 Level 3 - 4 mg/kgPhase 2 RP2D - 2 mg/kgTotal
Mean59.3 ± 11.1565.8 ± 7.1469.5 ± 10.0869.4 ± 6.3367.1 ± 8.14
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1 Level 1 - 1 mg/kgPhase 1 Level 2 - 2 mg/kgPhase 1 Level 3 - 4 mg/kgPhase 2 RP2D - 2 mg/kgTotal
Female03328
Male331714
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1 Level 1 - 1 mg/kgPhase 1 Level 2 - 2 mg/kgPhase 1 Level 3 - 4 mg/kgPhase 2 RP2D - 2 mg/kgTotal
Hispanic or Latino00000
Not Hispanic or Latino364922
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1 Level 1 - 1 mg/kgPhase 1 Level 2 - 2 mg/kgPhase 1 Level 3 - 4 mg/kgPhase 2 RP2D - 2 mg/kgTotal
American Indian or Alaska Native00000
Asian00011
Native Hawaiian or Other Pacific Islander00000
Black or African American00011
White364720
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Phase 1 Level 1 - 1 mg/kgPhase 1 Level 2 - 2 mg/kgPhase 1 Level 3 - 4 mg/kgPhase 2 RP2D - 2 mg/kgTotal
United States364922
ECOG Performance Status
ECOG Performance Status(Participants)Phase 1 Level 1 - 1 mg/kgPhase 1 Level 2 - 2 mg/kgPhase 1 Level 3 - 4 mg/kgPhase 2 RP2D - 2 mg/kgTotal
ECOG 0320712
ECOG 1044210
RAI Stage
RAI Stage(Participants)Phase 1 Level 1 - 1 mg/kgPhase 1 Level 2 - 2 mg/kgPhase 1 Level 3 - 4 mg/kgPhase 2 RP2D - 2 mg/kgTotal
Stage I00033
Stage II21003
Stage III01102
Stage IV143614
Disease Status at Screening
Disease Status at Screening(Participants)Phase 1 Level 1 - 1 mg/kgPhase 1 Level 2 - 2 mg/kgPhase 1 Level 3 - 4 mg/kgPhase 2 RP2D - 2 mg/kgTotal
Previously Untreated CLL01067
Refractory CLL01102
Relapse CLL343313
08

Study locations

1 site
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Oct 2018, 35 months.

Results were first posted in Dec 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2015
First posted
Sep 23, 2015
StartActual
Nov 9, 2015
Primary completionActual
Oct 29, 2018
CompletionActual
Sep 25, 2019
Results first posted
Dec 17, 2019
Last update
Dec 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02557516
Lead sponsor
Innate Pharma
Responsible party
Sponsor
First posted
Sep 23, 2015
Start date
Nov 9, 2015
Primary completion
Oct 29, 2018
Completion
Sep 25, 2019
Results posted
Dec 17, 2019
Last update
Dec 17, 2019

Study contacts

Kerry A Rogers, MD
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Monalizumab

Start the discussion